Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
ID | Components | Size |
EP146-C01 | High-bind Plate | 1 plate |
EP146-C02 | Human IL-6 R alpha | 15 μg |
EP146-C03 | Biotinylated Human IL-6 | 10 μg |
EP146-C04 | Anti-IL-6 Neutralizing Antibody | 10 μg |
EP146-C05 | Streptavidin-HRP | 10 μg |
EP146-C06 | Coating Buffer | 12 mL |
EP146-C07 | 10xWashing Buffer | 50 mL |
EP146-C08 | Blocking Buffer | 50 mL |
EP146-C09 | Substrate Solution | 12 mL |
EP146-C10 | Stop Solution | 7 mL |
This kit is used as a tool to aid in optimal purification process development and in routine quality control of in-process streams as well as final product by various biotechnological processes such as cell or tissue culture.
It is for research use only.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Your experiment will include 4 simple steps:
a) Coat the plate with human IL-6 R alpha.
b) Add your molecule of interest to the tests.
c) Add human IL-6-Biotin to bind the coated IL-6 R alpha.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the half maximal inhibitory concentration (IC50) of your compound to IL-6: IL-6 R alpha binding will be determined by comparing OD readings among different experimental groups.
INHIBITION OF IL-6 [Biotinylated]: IL-6 R alpha BINDING BY ANTI-IL6 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-IL-6 Neutralizing antibody (Catalog # EP146-C04) (1:1 serial dilution, from 10 μg/mL to 0.01μg/mL) was added into Biotinylated IL-6: IL-6 R alpha binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Lenalidomide | IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997; STAR-LLD | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | United States | Myelodysplastic Syndromes | Bristol Myers Squibb Srlcompany | 2005-12-27 | Lymphoma, T-Cell, Peripheral; Optic Nerve Glioma; Intestinal Neoplasms; Immunoproliferative Small Intestinal Disease; Solid tumours; Bone Marrow Neoplasms; Lymphoma, B-Cell, Marginal Zone; Kidney Neoplasms; Leukemia; Liver Neoplasms; Hematologic Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Ependymoma; HIV Infections; Ovarian Neoplasms; Medulloblastoma; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Plaque, Amyloid; Rhabdoid Tumor; Anemia, Refractory, with Excess of Blasts; Glioblastoma; Smoldering Multiple Myeloma; Anemia, Refractory; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Myelodysplastic Syndromes; Hypothalamic Neoplasms; Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Blood Protein Disorders; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Acute; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Multiple Myeloma; Leukemia, Megakaryoblastic, Acute; Oligodend | Details |
Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Immune System Diseases; Psoriasis | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis | Details | ||
Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2013-02-08 | Pulmonary Fibrosis; Atypical Squamous Cells of the Cervix; Sarcoma, Kaposi; Anemia, Sickle Cell; Neurofibromatosis 1; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Waldenstrom Macroglobulinemia; Glioma; Primary Myelofibrosis; Sarcoma; Thrombocytosis; Prostatic Neoplasms; Lung Diseases, Interstitial; Medulloblastoma; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Plasmacytoma; Kidney Diseases; Pancreatic Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myeloproliferative Disorders; Graft vs Host Disease; Scleroderma, Systemic; Polycythemia Vera; Bone Marrow Neoplasms; Solid tumours | Details |
Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | United States | Multicentric Castleman's Disease (MCD) | Janssen Biotech Inc | 2014-04-23 | Psychotic Disorders; Leukemia, Large Granular Lymphocytic; Lymphoma, Non-Hodgkin; Lung Neoplasms; Thrombocytopenia; Colorectal Neoplasms; Castleman Disease; Primary Myelofibrosis; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Multicentric Castleman's Disease (MCD); Lung Diseases; Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Multiple Myeloma; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Respiratory Tract Diseases; Schizophrenia; Pneumonia; Carcinoma, Renal Cell; Polycythemia Vera; Kidney Neoplasms; Respiratory Tract Infections; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1 | Details |
Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Tissue Adhesions; Cicatrix | Details |
Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease | Details |
Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Solid tumours; Hematopoietic stem cell transplantation (HSCT); Leukemia; HIV Infections; Graft vs Host Disease; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Plc | Myocardial Infarction; Heart Failure; Anemia; Atherosclerosis; Cardiovascular Diseases; Inflammation; Renal Insufficiency, Chronic; Systemic Inflammatory Response Syndrome | Details |
Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Kidney Failure, Chronic; Stomatitis | Details |
RO-7200220 | RO-7200220 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Macular Edema; Diabetic macular oedema | Details |
PF-04236921 | PF-4236921; PF-04236921; TOUR006; TOUR-006 | Phase 2 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic; Crohn Disease | Details |
Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
KSI-501 | KSI-501 | Phase 2 Clinical | Kodiak Sciences Inc | Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Uveitis | Details |
Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Frailty; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
RG-6179 | RG-6179 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Diabetic macular oedema | Details |
MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
NEX-20A | NEX-20A | Phase 1 Clinical | Nanexa AB | Multiple Myeloma | Details |
Wogonin | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Details |
This web search service is supported by Google Inc.